Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02659293
• Other study ID #: IRB15-1286
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: April 26, 2016
• Est. completion date: November 2026

Study information

• Verified date: April 2023
• Source: University of Chicago
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 3 randomized trial of carfilzomib, lenalidomide, dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma, eligible to subjects who completed autologous stem cell transplant for symptomatic myeloma who are considered for lenalidomide maintenance.

Description:

Primary Objective:

• To compare progression free survival between Kyprolis (Carfilzomib), Revlimid (lenalidomide), Dexamethasone (KRd) arm and lenalidomide arm

Secondary Objectives

• To determine the rate of minimal residual negative disease (MRD) at 6 and 12 months after randomization

• To compare the efficacy (rate of partial response, very good partial response, complete response, and stringent complete response) of KRd vs. Lenalidomide alone after randomization

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 180
• Est. completion date: November 2026
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients who completed single autologous stem cell transplant after completion of at most 2 induction regimens (excluding dexamethasone alone) and are in at least stable disease in the first 100 days after stem cell transplantation.

2. Patients must be within 12 months of initiation of induction therapy and must have had not more than 2 prior induction regimens.

3. Bone marrow specimen will be required at study entry; available DNA sample will be used for calibration step for MRD evaluation by gene sequencing.

4. Males and females = 18 years of age

5. ECOG performance status of 0-1

6. Adequate hepatic function, with bilirubin = 1.5 x ULN and aspirate aminotransferase (AST) and alanine aminotransferase (ALT) = 3 x ULN

7. ANC = 1.0 x 109/L, hemoglobin = 8 g/dL, platelet count = 75 x 109/L.

8. Calculated creatinine clearance (by Cockcroft-Gault) = 50 ml/min or serum creatinine below 2 mg/dL

9. Females of childbearing potential (FCBP) must have 2 negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to initiating lenalidomide. The first pregnancy test must be performed within 10-14 days before and the second pregnancy test must be performed within 24 hours before lenalidomide is prescribed for Cycle 1 (prescriptions must be filled within 7 days).

10. FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting lenalidomide; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study.

UCM IRB CRd vs. R Version 1.0 Page 11

11. Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.

12. All study participants in the US must be consented to and registered into the mandatory Revlimid REMS® program and be willing and able to comply with the requirements of Revlimid REMS®.

13. Voluntary written informed consent

Exclusion Criteria:

1. Patients who have had more than 12 months of prior therapy. Patients outside of this window may be considered for inclusion on a case-by-case basis.

2. Patients who progressed after initial therapy.

1. Subjects whose therapy changed due to suboptimal response, intolerance, etc., remain eligible, provided they do not meet criteria for progression.

2. No more than two regimens for induction will be allowed excluding dexamethasone alone.

3. Evidence of progressive disease as per International Myeloma Working Group (IMWG) criteria

4. Patients who have already started or received post-transplant maintenance or consolidation regimen

5. Patients not able to tolerate lenalidomide or carfilzomib or dexamethasone

6. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)

7. Plasma cell leukemia

8. Waldenström's macroglobulinemia or IgM myeloma

9. Peripheral neuropathy = Grade 2 at screening

10. Diarrhea > Grade 1 in the absence of antidiarrheals

11. CNS involvement

12. Pregnant or lactating females

13. Radiotherapy within 14 days before randomization. Seven days may be considered if to single area.

14. Major surgery within 3 weeks prior to first dose

15. Myocardial infarction within 6 months prior to enrollment, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities

16. Prior or concurrent deep vein thrombosis or pulmonary embolism

17. Rate-corrected QT interval of electrocardiograph (QTc) > 470 msec on a 12-lead ECG during screening

18. Uncontrolled hypertension or diabetes

19. Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose

20. Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.

21. Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3 years except a) adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or prostate cancer < Gleason Grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone

22. Any clinically significant medical disease or condition that, in the Treating Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Lenalidomide
Cycle 1: 15 mg days 1-21 Cycles 2-4: 25 mg days 1-21 if tolerated, otherwise continue at lower dose Cycles 5 and beyond: best tolerated dose days 1-21
• Carfilzomib
Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8,9 of cycle 1) will be al12,lowed at the treating physician's discretion. Cycle 2-4: 36 mg/m2 if tolerated Days 1, 2, 8, 9, 15, 16 Cycles 5-8 (patients that are MRD- and have no risk factors at the end of cycle 6) and Cycle 5 - 36 (for MRD+ patients and high risk patients at the end of cycle 6): best tolerated dose Days 1, 2, 15, 16
• Dexamethasone
Cycles 1 - 4: 20 mg PO or IV per dose Days 1, 8, 15, 22 Cycles 5+: 20 mg or best tolerated dose PO or IV per dose Days 1, 8, 15, 22
• Lenalidomide (Control)
Cycles 1-4: Days 1-28. Lenalidomide will begin at a dose of 10 mg PO daily (2 capsules per day). After three months, the dose will be increased, provided ANC = 1,000/µL, platelet count = 75,000/µL, and all nonhematologic toxicity is = grade 1, to 15 mg PO daily (3 capsules per day). Cycles 5 and beyond: best tolerated dose days 1-28

Locations

Country	Name	City	State
Poland	Polish Myeloma Consortium	Poznan
United States	University of Chicago	Chicago	Illinois
United States	Wayne State University - Karmanos Cacner Institute	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
University of Chicago

Countries where clinical trial is conducted

United States,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival rates in participants receiving drug combination	Measurement of time to disease worsening as measured by International Myeloma Working Group (IMWG) response criteria.	4 years
Secondary	Rate of minimal residual negative disease (MRD) in participants receiving drug combination	Calculation of number of participants with MRD-negative disease.	3 years
Secondary	Response rate in participants receiving drug combination	Number of participants with disease response (e.g. improvement) as measured by International Myeloma Working Group (IMWG) response criteria.	3 years
Secondary	Treatment-related side effects	Number of participants with grade 2 or greater treatment-related side effects as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0	From date of screening until end of treatment